BioSpace News Archive

Bexson Biomedical, Inc. announced Bexson and Stevanato Group, a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, have been jointly awarded the Parenteral Drug Association’s 2022 Drug Delivery Innovation Partnership Award.

OSF HealthCare selected CareSignal, a Lightbeam company, to offer Deviceless Remote Patient Monitoring® (RPM) and help power its enterprise-wide digital health solution, OSF OnCall Connect.

GE Healthcare and AMC Health today announced a collaboration that allows clinicians to offer Remote Patient Monitoring (RPM) as a virtual care solution that extends patient care outside the hospital to the home environment.

Sun Nuclear today announced that it is developing new Quality Management solutions, in collaboration with Accuray, for the company’s Radixact® System with Synchrony®, which enables real-time, personalized adaptive radiation therapy. Initial innovations from the collaboration will be featured in the Sun Nuclear booth (980) at the ASTRO Annual Meeting.

dentalcorp Holdings Ltd. announced today that it will release its third quarter 2022 financial results before market open on November 9, 2022.

City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced that the first patient to receive its novel, promising cancer medicine AOH1996 is doing well.

Nabsys, the pioneer in electronic whole-genome mapping, announced that Justin Bingham has joined the company as its Chief Commercial Officer.

FUJIFILM Irvine Scientific, Inc, today announced that its PRIME-XV Stem FreezIS DMSO-Free* cryopreservation medium is to be used as an excipient in a FDA-authorized clinical trial conducted by Vitro Biopharma.

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) (“Calliditas”) today announced Kidney International has published the successful results from NefIgArd Part A, their pivotal Phase 3, randomized, double-blind, placebo-controlled, multicenter study.

Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that asunercept showed statistically significant benefits for hospitalized COVID-19 patients in the ASUNCTIS trial.